# Specific Molecular Signatures Predict Neoadjuvant Chemotherapy Response in Cervical Cancer

> **NCT03229187** · — · UNKNOWN · sponsor: **Huazhong University of Science and Technology** · enrollment: 240 (estimated)

## Conditions studied

- Uterine Cervical Neoplasms
- Cervical Cancer
- Uterine Cervical Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT03229187
- **Lead sponsor:** Huazhong University of Science and Technology
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-01-01
- **Primary completion:** 2020-09-30
- **Final completion:** 2020-09-30
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2020-06-16

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03229187

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03229187, "Specific Molecular Signatures Predict Neoadjuvant Chemotherapy Response in Cervical Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03229187. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*